Lunsumio Velo
Lunsumio Velo ingredients
| Active ingredient | Strength |
|---|---|
| Mosunetuzumab | 45 mg/mL, 5 mg/.5mL |
What Lunsumio Velo is used for
The FDA lists the approved uses on the official label (below). In the EU, mosunetuzumab is approved as Lunsumio for:
Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Lunsumio Velo
- Generic name
- Mosunetuzumab
- Made by
- Genentech, Inc.
- Forms
- Injection
- Given
- Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761263
- On the US market since
- 2025
Official information
- Lunsumio Velo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Mosunetuzumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lunsumio Velo?
Lunsumio Velo (Mosunetuzumab) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Lunsumio Velo?
Lunsumio Velo contains Mosunetuzumab (45 mg/mL, 5 mg/.5mL).
Is Lunsumio Velo approved in Europe?
The same active substance is approved in the EU as Lunsumio.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA